7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cell type-specific lipid storage changes in Parkinson’s disease patient brains are recapitulated by experimental glycolipid disturbance

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          Recently, the field of Parkinson’s disease biology has shifted attention away from pure proteinotoxic hypotheses to emphasize primary cellular insults, including glycolipid disturbances. In this work, dopaminergic neurons in the Parkinson’s disease-vulnerable region of substantia nigra were found to accumulate neutral lipids, whereas in the same tissues, astrocytes have reduced lipid content, and resident microglia (a form of brain macrophage) show overall accumulation of lipids associated with inflammation. These changes were reproduced experimentally by blocking a specific lysosomal hydrolase in mice, generating a glycolipid accumulation in the animals. Based on these findings, it is reasonable to propose that restoring lipid homeostasis between neurons, astrocytes, and microglia could potentially influence PD pathogenesis and disease progression.

          Abstract

          Neurons are dependent on proper trafficking of lipids to neighboring glia for lipid exchange and disposal of potentially lipotoxic metabolites, producing distinct lipid distribution profiles among various cell types of the central nervous system. Little is known of the cellular distribution of neutral lipids in the substantia nigra (SN) of Parkinson’s disease (PD) patients and its relationship to inflammatory signaling. This study aimed to determine human PD SN neutral lipid content and distribution in dopaminergic neurons, astrocytes, and microglia relative to age-matched healthy subject controls. The results show that while total neutral lipid content was unchanged relative to age-matched controls, the levels of whole SN triglycerides were correlated with inflammation-attenuating glycoprotein non-metastatic melanoma protein B (GPNMB) signaling in human PD SN. Histological localization of neutral lipids using a fluorescent probe (BODIPY) revealed that dopaminergic neurons and midbrain microglia significantly accumulated intracellular lipids in PD SN, while adjacent astrocytes had a reduced lipid load overall. This pattern was recapitulated by experimental in vivo inhibition of glucocerebrosidase activity in mice. Agents or therapies that restore lipid homeostasis among neurons, astrocytes, and microglia could potentially correct PD pathogenesis and disease progression.

          Related collections

          Most cited references73

          • Record: found
          • Abstract: found
          • Article: not found

          A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.

          Alzheimer's disease (AD) is a detrimental neurodegenerative disease with no effective treatments. Due to cellular heterogeneity, defining the roles of immune cell subsets in AD onset and progression has been challenging. Using transcriptional single-cell sorting, we comprehensively map all immune populations in wild-type and AD-transgenic (Tg-AD) mouse brains. We describe a novel microglia type associated with neurodegenerative diseases (DAM) and identify markers, spatial localization, and pathways associated with these cells. Immunohistochemical staining of mice and human brain slices shows DAM with intracellular/phagocytic Aβ particles. Single-cell analysis of DAM in Tg-AD and triggering receptor expressed on myeloid cells 2 (Trem2)(-/-) Tg-AD reveals that the DAM program is activated in a two-step process. Activation is initiated in a Trem2-independent manner that involves downregulation of microglia checkpoints, followed by activation of a Trem2-dependent program. This unique microglia-type has the potential to restrict neurodegeneration, which may have important implications for future treatment of AD and other neurodegenerative diseases. VIDEO ABSTRACT.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Parkinson disease

            Parkinson disease is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age. Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease. Multiple other cell types throughout the central and peripheral autonomic nervous system are also involved, probably from early disease onwards. Although clinical diagnosis relies on the presence of bradykinesia and other cardinal motor features, Parkinson disease is associated with many non-motor symptoms that add to overall disability. The underlying molecular pathogenesis involves multiple pathways and mechanisms: α-synuclein proteostasis, mitochondrial function, oxidative stress, calcium homeostasis, axonal transport and neuroinflammation. Recent research into diagnostic biomarkers has taken advantage of neuroimaging in which several modalities, including PET, single-photon emission CT (SPECT) and novel MRI techniques, have been shown to aid early and differential diagnosis. Treatment of Parkinson disease is anchored on pharmacological substitution of striatal dopamine, in addition to non-dopaminergic approaches to address both motor and non-motor symptoms and deep brain stimulation for those developing intractable L-DOPA-related motor complications. Experimental therapies have tried to restore striatal dopamine by gene-based and cell-based approaches, and most recently, aggregation and cellular transport of α-synuclein have become therapeutic targets. One of the greatest current challenges is to identify markers for prodromal disease stages, which would allow novel disease-modifying therapies to be started earlier.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Alpha-synuclein in Lewy bodies.

                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc Natl Acad Sci U S A
                pnas
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                3 November 2020
                15 October 2020
                15 October 2020
                : 117
                : 44
                : 27646-27654
                Affiliations
                [1] aNeuroregeneration Institute, McLean Hospital/Departments of Neurology and Psychiatry, Harvard Medical School , Belmont, MA 02478
                [2] bNeuroregeneration Institute, McLean Hospital/Harvard Medical School, Belmont, MA 02478
                Author notes
                1To whom correspondence may be addressed. Email: obrekk@ 123456mclean.harvard.edu or isacson@ 123456hms.harvard.edu .

                Edited by Solomon H. Snyder, Johns Hopkins University School of Medicine, Baltimore, MD, and approved September 2, 2020 (received for review February 17, 2020)

                Author contributions: O.R.B., P.J.H., and O.I. designed research; O.R.B., J.R.H., and S.L. performed research; O.R.B., J.R.H., S.L., P.J.H., and O.I. analyzed data; and O.R.B., S.L., P.J.H., and O.I. wrote the paper.

                2Present address: School of Clinical Medicine, Addenbrooke’s Hospital/University of Cambridge, Cambridge, CB2 0QQ Cambridgeshire, UK.

                Author information
                https://orcid.org/0000-0002-5619-4022
                https://orcid.org/0000-0002-9698-4707
                https://orcid.org/0000-0003-2829-2941
                Article
                202003021
                10.1073/pnas.2003021117
                7959493
                33060302
                789b2b52-767b-4e32-b871-372a3046ebda
                Copyright © 2020 the Author(s). Published by PNAS.

                This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

                History
                Page count
                Pages: 9
                Funding
                Funded by: HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 100000065
                Award ID: 1R01NS092667
                Award Recipient : Penelope J Hallett
                Funded by: HHS | NIH | National Institute on Aging (NIA) 100000049
                Award ID: R01AG060195
                Award Recipient : Ole Isacson
                Funded by: U.S. Department of Defense (DOD) 100000005
                Award ID: W81XWH2010368
                Award Recipient : Penelope J Hallett Award Recipient : Ole Isacson
                Funded by: The Consolidated Anti-Aging Foundation
                Award ID: N/A
                Award Recipient : Oeystein R Brekk Award Recipient : Ole Isacson
                Funded by: The Orchard Foundation
                Award ID: N/A
                Award Recipient : Oeystein R Brekk Award Recipient : Ole Isacson
                Funded by: Harold and Ronna Cooper Postdoctoral Fellowship for Parkinson's Disease Research
                Award ID: N/A
                Award Recipient : Oeystein R Brekk Award Recipient : Ole Isacson
                Funded by: U.S. Department of Defense (DOD) 100000005
                Award ID: W81XWH2010371
                Award Recipient : Penelope J Hallett Award Recipient : Ole Isacson
                Categories
                Biological Sciences
                Neuroscience

                parkinson’s disease,glucocerebrosidase,lipids,neurons,astrocytes

                Comments

                Comment on this article